Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CDKN2C |
| Gene Name: | CDKN2C |
| Protein Full Name: | Cyclin-dependent kinase 4 inhibitor C |
| Alias: | Cyclin-dependent kinase 6 inhibitor;p18-INK4c;p18-INK6 |
| Mass (Da): | 18127 |
| Number AA: | 168 |
| UniProt ID: | P42773 |
| Locus ID: | 1031 |
| COSMIC ID: | CDKN2C |
| Gene location on chromosome: | 1p32.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20503 |
| Percent of cancer specimens with mutations: | 0.18 |
| Gene undergoes hypermethylation: | Yes in pituitary adenoma |
| Normal role description: | Inhibits Cyclin-dependent kinase 4 (CDK4) which is responsible forprogression through G1 of the cell cycle. Given that CDK4 is often overexpressed in human tumors, this inhibitor CDKN2C functions as a tumour suppressor and loss of function of CDKN2C will facilitate oncogenesis via increasing CDK4 activity |